No evidence that GATA3 rs570613 SNP modifies breast cancer risk

Sharon E. Johnatty; Fergus J. Couch; Zachary Fredericksen; Robert Tarrell; Amanda B. Spurdle; Jonathan Beesley; Xiaoqing Chen; Daphne Gschwantler-Kaulich; Christian F. Singer; Christine Fuerhauser; Anneliese Fink-Retter; Susan M. Domchek; Katherine L. Nathanson; Vernon S. Pankratz; Noralane M. Lindor; Andrew K. Godwin; Maria A. Caligo; John Hopper; Melissa C. Southey; Graham G. Giles; Christina Justenhoven; Hiltrud Brauch; Ute Hamann; Yon Dschun Ko; Tuomas Heikkinen; Kirsimari Aaltonen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Per Hall; Kamila Czene; Jianjun Liu; Susan Peock; Margaret Cook; Radka Platte; D. Gareth Evans; Fiona Lalloo; Rosalind Eeles; Gabriella Pichert; Diana Eccles; Rosemarie Davidson; Trevor Cole; Jackie Cook; Fiona Douglas; Carol Chu; Shirley Hodgson; Joan Paterson; Frans B.L. Hogervorst; Matti A. Rookus; Caroline Seynaeve; Juul Wijnen; Maaike Vreeswijk; Marjolijn Ligtenberg; Rob B. Van Der Luijt; Theo A.M. Van Os; Hans J.P. Gille; Marinus J. Blok; Claudine Issacs; Manjeet K. Humphreys; Lesley McGuffog; Sue Healey; Olga Sinilnikova; Antonis C. Antoniou; Douglas F. Easton; Georgia Chenevix-Trench

doi:10.1007/s10549-008-0257-1

No evidence that GATA3 rs570613 SNP modifies breast cancer risk

Sharon E. Johnatty, Fergus J. Couch, Zachary Fredericksen, Robert Tarrell, Amanda B. Spurdle, Jonathan Beesley, Xiaoqing Chen, Daphne Gschwantler-Kaulich, Christian F. Singer, Christine Fuerhauser, Anneliese Fink-Retter, Susan M. Domchek, Katherine L. Nathanson, Vernon S. Pankratz, Noralane M. Lindor, Andrew K. Godwin, Maria A. Caligo, John Hopper, Melissa C. Southey, Graham G. GilesChristina Justenhoven, Hiltrud Brauch, Ute Hamann, Yon Dschun Ko, Tuomas Heikkinen, Kirsimari Aaltonen, Kristiina Aittomäki, Carl Blomqvist, Heli Nevanlinna, Per Hall, Kamila Czene, Jianjun Liu, Susan Peock, Margaret Cook, Radka Platte, D. Gareth Evans, Fiona Lalloo, Rosalind Eeles, Gabriella Pichert, Diana Eccles, Rosemarie Davidson, Trevor Cole, Jackie Cook, Fiona Douglas, Carol Chu, Shirley Hodgson, Joan Paterson, Frans B.L. Hogervorst, Matti A. Rookus, Caroline Seynaeve, Juul Wijnen, Maaike Vreeswijk, Marjolijn Ligtenberg, Rob B. Van Der Luijt, Theo A.M. Van Os, Hans J.P. Gille, Marinus J. Blok, Claudine Issacs, Manjeet K. Humphreys, Lesley McGuffog, Sue Healey, Olga Sinilnikova, Antonis C. Antoniou, Douglas F. Easton, Georgia Chenevix-Trench

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P _trend = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (OR_per-allele = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (OR_per-allele = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RR_per-allele = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RR_per-allele = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.

Original language	English (US)
Pages (from-to)	371-379
Number of pages	9
Journal	Breast Cancer Research and Treatment
Volume	117
Issue number	2
DOIs	https://doi.org/10.1007/s10549-008-0257-1
State	Published - Sep 2009

Keywords

BRCA1 and BRCA2
Breast cancer
GATA3
Polymorphism
Risk

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-008-0257-1

Cite this

Johnatty, S. E., Couch, F. J., Fredericksen, Z., Tarrell, R., Spurdle, A. B., Beesley, J., Chen, X., Gschwantler-Kaulich, D., Singer, C. F., Fuerhauser, C., Fink-Retter, A., Domchek, S. M., Nathanson, K. L., Pankratz, V. S., Lindor, N. M., Godwin, A. K., Caligo, M. A., Hopper, J., Southey, M. C., ... Chenevix-Trench, G. (2009). No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 117(2), 371-379. https://doi.org/10.1007/s10549-008-0257-1

Johnatty, SE, Couch, FJ, Fredericksen, Z, Tarrell, R, Spurdle, AB, Beesley, J, Chen, X, Gschwantler-Kaulich, D, Singer, CF, Fuerhauser, C, Fink-Retter, A, Domchek, SM, Nathanson, KL, Pankratz, VS, Lindor, NM, Godwin, AK, Caligo, MA, Hopper, J, Southey, MC, Giles, GG, Justenhoven, C, Brauch, H, Hamann, U, Ko, YD, Heikkinen, T, Aaltonen, K, Aittomäki, K, Blomqvist, C, Nevanlinna, H, Hall, P, Czene, K, Liu, J, Peock, S, Cook, M, Platte, R, Gareth Evans, D, Lalloo, F, Eeles, R, Pichert, G, Eccles, D, Davidson, R, Cole, T, Cook, J, Douglas, F, Chu, C, Hodgson, S, Paterson, J, Hogervorst, FBL, Rookus, MA, Seynaeve, C, Wijnen, J, Vreeswijk, M, Ligtenberg, M, Van Der Luijt, RB, Van Os, TAM, Gille, HJP, Blok, MJ, Issacs, C, Humphreys, MK, McGuffog, L, Healey, S, Sinilnikova, O, Antoniou, AC, Easton, DF & Chenevix-Trench, G 2009, 'No evidence that GATA3 rs570613 SNP modifies breast cancer risk', Breast Cancer Research and Treatment, vol. 117, no. 2, pp. 371-379. https://doi.org/10.1007/s10549-008-0257-1

@article{6c705baea73148f0a362db6246d98448,

title = "No evidence that GATA3 rs570613 SNP modifies breast cancer risk",

abstract = "GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P trend = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (ORper-allele = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (ORper-allele = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RRper-allele = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RRper-allele = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.",

keywords = "BRCA1 and BRCA2, Breast cancer, GATA3, Polymorphism, Risk",

author = "Johnatty, {Sharon E.} and Couch, {Fergus J.} and Zachary Fredericksen and Robert Tarrell and Spurdle, {Amanda B.} and Jonathan Beesley and Xiaoqing Chen and Daphne Gschwantler-Kaulich and Singer, {Christian F.} and Christine Fuerhauser and Anneliese Fink-Retter and Domchek, {Susan M.} and Nathanson, {Katherine L.} and Pankratz, {Vernon S.} and Lindor, {Noralane M.} and Godwin, {Andrew K.} and Caligo, {Maria A.} and John Hopper and Southey, {Melissa C.} and Giles, {Graham G.} and Christina Justenhoven and Hiltrud Brauch and Ute Hamann and Ko, {Yon Dschun} and Tuomas Heikkinen and Kirsimari Aaltonen and Kristiina Aittom{\"a}ki and Carl Blomqvist and Heli Nevanlinna and Per Hall and Kamila Czene and Jianjun Liu and Susan Peock and Margaret Cook and Radka Platte and {Gareth Evans}, D. and Fiona Lalloo and Rosalind Eeles and Gabriella Pichert and Diana Eccles and Rosemarie Davidson and Trevor Cole and Jackie Cook and Fiona Douglas and Carol Chu and Shirley Hodgson and Joan Paterson and Hogervorst, {Frans B.L.} and Rookus, {Matti A.} and Caroline Seynaeve and Juul Wijnen and Maaike Vreeswijk and Marjolijn Ligtenberg and {Van Der Luijt}, {Rob B.} and {Van Os}, {Theo A.M.} and Gille, {Hans J.P.} and Blok, {Marinus J.} and Claudine Issacs and Humphreys, {Manjeet K.} and Lesley McGuffog and Sue Healey and Olga Sinilnikova and Antoniou, {Antonis C.} and Easton, {Douglas F.} and Georgia Chenevix-Trench",

note = "Funding Information: FJC, ZF and RT and the MAYO study were supported in part by U.S. National Institutes of Health grants CA122340 and CA128978 and an award from the Breast Cancer Research Foundation. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. AOCS was funded by U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study). The ABCFS was supported by the National Health and Medical Research Council (NHMRC) of Australia (#145604), the U.S. National Institutes of Health (RO1 CA102740-01A2) and by the National Cancer Institute, National Institutes of Health under RFA # CA-95-011 through cooperative agreements with members of the Breast Cancer Family Registry (Breast CFR) and PIs {\textquoteleft}{\textquoteleft}Cancer Care Ontario (UO1 CA69467){\textquoteright}{\textquoteright}, {\textquoteleft}{\textquoteleft}Columbia University (U01 CA69398){\textquoteright}{\textquoteright}, {\textquoteleft}{\textquoteleft}Fox Chase Cancer Center (U01 CA69631){\textquoteright}{\textquoteright}, {\textquoteleft}{\textquoteleft}Huntsman Cancer Institute (U01 CA69446){\textquoteright}{\textquoteright}, {\textquoteleft}{\textquoteleft}Northern California Cancer Center (U01 CA69417){\textquoteright}{\textquoteright}, {\textquoteleft}{\textquoteleft}University of Melbourne (U01 CA69638){\textquoteright}{\textquoteright}. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of collaborating centers in the Breast CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the Breast CFR. The Australian Breast Cancer Family Study was initially supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation. SWE-BRCA is supported by grants from the Swedish Cancer Society and Swedish County Council. The HEB-CS study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (110663), Finnish Cancer Society and the Sigrid Juselius Foundation; This work was supported in part by the Fox Chase Cancer Center Ovarian Cancer SPORE, P50 CA83638, and the Eileen Stein-Jacoby Fund. CIMBA data management{\textquoteright}{\textquoteright} is funded by CR-UK. PBCS is supported by Fondazione Cassa di Risparmio. The GENICA study was Funding Information: Acknowledgments We wish to thank Claudine Isaacs for the samples from Georgetown; Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704 and 454508) for their contributions to this resourcekConFab; the AOCS Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb), all the clinical and scientific collaborators of AOCS (http://www. aocstudy.org/), the project staff, and collaborating institutions; Maggie Angelakos, Judi Maskiell and Gillian Dite (ABCFS); RN Hanna J{\"a}ntti for help with the patient data and the Finnish Cancer registry for the cancer data (HEBCS); Anne-Catherine Spiess and Georg Pfeiler (MUV); Betsy Bove, Mary Daly, John Malick, Beth Stearman, JoEllen Weaver (FCCC); Gisella Lombardi (PBCS); Beate Pesch, Volker Harth and Thomas Br{\"u}ning for recruitment of GENICA study subjects and collection of epidemiological data. Funding Information: supported by the German Human Genome Project and funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114. Genotyping analysis was supported by the Robert Bosch Foundation of Medical Research, Stuttgart, Germany. The HEBON study and Anouk Pijpe are funded by the Dutch Cancer Society grant NKI2004-3088, NKI 2007-3756. GCT, JLH, MS and PW are supported by the NHMRC. Antonis Antoniou, Lesley McGuffog, Margaret Cook, Susan Peock and EMBRACE are funded by Cancer Research–UK. We would also like to thank the 17,100 women who participated in these studies.",

year = "2009",

month = sep,

doi = "10.1007/s10549-008-0257-1",

language = "English (US)",

volume = "117",

pages = "371--379",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - No evidence that GATA3 rs570613 SNP modifies breast cancer risk

AU - Johnatty, Sharon E.

AU - Couch, Fergus J.

AU - Fredericksen, Zachary

AU - Tarrell, Robert

AU - Spurdle, Amanda B.

AU - Beesley, Jonathan

AU - Chen, Xiaoqing

AU - Gschwantler-Kaulich, Daphne

AU - Singer, Christian F.

AU - Fuerhauser, Christine

AU - Fink-Retter, Anneliese

AU - Domchek, Susan M.

AU - Nathanson, Katherine L.

AU - Pankratz, Vernon S.

AU - Lindor, Noralane M.

AU - Godwin, Andrew K.

AU - Caligo, Maria A.

AU - Hopper, John

AU - Southey, Melissa C.

AU - Giles, Graham G.

AU - Justenhoven, Christina

AU - Brauch, Hiltrud

AU - Hamann, Ute

AU - Ko, Yon Dschun

AU - Heikkinen, Tuomas

AU - Aaltonen, Kirsimari

AU - Aittomäki, Kristiina

AU - Blomqvist, Carl

AU - Nevanlinna, Heli

AU - Hall, Per

AU - Czene, Kamila

AU - Liu, Jianjun

AU - Peock, Susan

AU - Cook, Margaret

AU - Platte, Radka

AU - Gareth Evans, D.

AU - Lalloo, Fiona

AU - Eeles, Rosalind

AU - Pichert, Gabriella

AU - Eccles, Diana

AU - Davidson, Rosemarie

AU - Cole, Trevor

AU - Cook, Jackie

AU - Douglas, Fiona

AU - Chu, Carol

AU - Hodgson, Shirley

AU - Paterson, Joan

AU - Hogervorst, Frans B.L.

AU - Rookus, Matti A.

AU - Seynaeve, Caroline

AU - Wijnen, Juul

AU - Vreeswijk, Maaike

AU - Ligtenberg, Marjolijn

AU - Van Der Luijt, Rob B.

AU - Van Os, Theo A.M.

AU - Gille, Hans J.P.

AU - Blok, Marinus J.

AU - Issacs, Claudine

AU - Humphreys, Manjeet K.

AU - McGuffog, Lesley

AU - Healey, Sue

AU - Sinilnikova, Olga

AU - Antoniou, Antonis C.

AU - Easton, Douglas F.

AU - Chenevix-Trench, Georgia

N1 - Funding Information: FJC, ZF and RT and the MAYO study were supported in part by U.S. National Institutes of Health grants CA122340 and CA128978 and an award from the Breast Cancer Research Foundation. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. AOCS was funded by U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study). The ABCFS was supported by the National Health and Medical Research Council (NHMRC) of Australia (#145604), the U.S. National Institutes of Health (RO1 CA102740-01A2) and by the National Cancer Institute, National Institutes of Health under RFA # CA-95-011 through cooperative agreements with members of the Breast Cancer Family Registry (Breast CFR) and PIs ‘‘Cancer Care Ontario (UO1 CA69467)’’, ‘‘Columbia University (U01 CA69398)’’, ‘‘Fox Chase Cancer Center (U01 CA69631)’’, ‘‘Huntsman Cancer Institute (U01 CA69446)’’, ‘‘Northern California Cancer Center (U01 CA69417)’’, ‘‘University of Melbourne (U01 CA69638)’’. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of collaborating centers in the Breast CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the Breast CFR. The Australian Breast Cancer Family Study was initially supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation. SWE-BRCA is supported by grants from the Swedish Cancer Society and Swedish County Council. The HEB-CS study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (110663), Finnish Cancer Society and the Sigrid Juselius Foundation; This work was supported in part by the Fox Chase Cancer Center Ovarian Cancer SPORE, P50 CA83638, and the Eileen Stein-Jacoby Fund. CIMBA data management’’ is funded by CR-UK. PBCS is supported by Fondazione Cassa di Risparmio. The GENICA study was Funding Information: Acknowledgments We wish to thank Claudine Isaacs for the samples from Georgetown; Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704 and 454508) for their contributions to this resourcekConFab; the AOCS Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb), all the clinical and scientific collaborators of AOCS (http://www. aocstudy.org/), the project staff, and collaborating institutions; Maggie Angelakos, Judi Maskiell and Gillian Dite (ABCFS); RN Hanna Jäntti for help with the patient data and the Finnish Cancer registry for the cancer data (HEBCS); Anne-Catherine Spiess and Georg Pfeiler (MUV); Betsy Bove, Mary Daly, John Malick, Beth Stearman, JoEllen Weaver (FCCC); Gisella Lombardi (PBCS); Beate Pesch, Volker Harth and Thomas Brüning for recruitment of GENICA study subjects and collection of epidemiological data. Funding Information: supported by the German Human Genome Project and funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114. Genotyping analysis was supported by the Robert Bosch Foundation of Medical Research, Stuttgart, Germany. The HEBON study and Anouk Pijpe are funded by the Dutch Cancer Society grant NKI2004-3088, NKI 2007-3756. GCT, JLH, MS and PW are supported by the NHMRC. Antonis Antoniou, Lesley McGuffog, Margaret Cook, Susan Peock and EMBRACE are funded by Cancer Research–UK. We would also like to thank the 17,100 women who participated in these studies.

PY - 2009/9

Y1 - 2009/9

N2 - GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P trend = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (ORper-allele = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (ORper-allele = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RRper-allele = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RRper-allele = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.

AB - GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P trend = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (ORper-allele = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (ORper-allele = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RRper-allele = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RRper-allele = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.

KW - BRCA1 and BRCA2

KW - Breast cancer

KW - GATA3

KW - Polymorphism

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=68949092457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949092457&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0257-1

DO - 10.1007/s10549-008-0257-1

M3 - Article

C2 - 19082709

AN - SCOPUS:68949092457

SN - 0167-6806

VL - 117

SP - 371

EP - 379

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

No evidence that GATA3 rs570613 SNP modifies breast cancer risk

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this